Literature DB >> 28661488

Response to Herbert et al.

Juna M de Vries1,2, Esther Kuperus1,2, Marianne Hoogeveen-Westerveld1,3, Marian A Kroos1,3, Stephan C A Wens1,2, Merel Stok1,3,4, Nadine A M E van der Beek1,2, Michelle E Kruijshaar1,4, Dimitris Rizopoulos5, Pieter A van Doorn1,2, Ans T van der Ploeg1,4, W W M Pim Pijnappel1,3,4.   

Abstract

Entities:  

Year:  2017        PMID： 28661488     DOI： 10.1038/gim.2017.49

Source DB:  PubMed          Journal:  Genet Med        ISSN： 1098-3600            Impact factor:   8.822


× No keyword cloud information.
  3 in total

1.  High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.

Authors:  Juna M de Vries; Nadine A M E van der Beek; Marian A Kroos; Lale Ozkan; Pieter A van Doorn; Susan M Richards; Crystal C C Sung; Jan-Dietert C Brugma; Adrienne A M Zandbergen; Ans T van der Ploeg; Arnold J J Reuser
Journal:  Mol Genet Metab       Date:  2010-08-14       Impact factor: 4.797

2.  Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Authors:  Elisa Masat; Pascal Laforêt; Marie De Antonio; Guillaume Corre; Barbara Perniconi; Nadjib Taouagh; Kuberaka Mariampillai; Damien Amelin; Wladimir Mauhin; Jean-Yves Hogrel; Catherine Caillaud; Giuseppe Ronzitti; Francesco Puzzo; Klaudia Kuranda; Pasqualina Colella; Roberto Mallone; Olivier Benveniste; Federico Mingozzi
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

3.  Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

Authors:  Juna M de Vries; Esther Kuperus; Marianne Hoogeveen-Westerveld; Marian A Kroos; Stephan C A Wens; Merel Stok; Nadine A M E van der Beek; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Genet Med       Date:  2016-06-30       Impact factor: 8.822
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.